Mainline Biosciences
Latest round
- Series A
Last raised
- Nov 2022
Total raised
- $14M
Investors
- 3
About Mainline Biosciences
0. It has branches in Shanghai and the United States to jointly promote the global peptide drug development process. The clinical development team has years of experience in managing pharmaceutical companies and has led the development and launch of major drugs such as Gleevec, Tasigna, Avastin, and Cabometyx. The company's main business is to develop innovative peptide drug conjugates (PDCs) using its proprietary multifunctional peptide drug discovery and optimization platform to meet unmet clinical needs in the field of oncology. The company's independently developed products include MB0151, the first PDC targeting SSTR2 for advanced solid tumors, and an AI-enhanced peptide therapy pipeline designed for precise toxin delivery through computer-assisted peptide sequence engineering. Its products are used in the fields of cancer immunotherapy and targeted therapy. The company generates revenue by licensing its PDC technology platform to pharmaceutical partners, collaborating on projects with global biotechnology companies, and advancing clinical-stage assets through strategic partnerships and government-funded oncology programs.
Who invested in Mainline Biosciences
3 investors across 1 round
See all investors in Mainline Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 9, 2022
Amount
$14M
Investors
Questions about Mainline Biosciences
Who invested in Mainline Biosciences?
Mainline Biosciences has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Mainline Biosciences raised?
Mainline Biosciences has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Mainline Biosciences last raise money?
Mainline Biosciences's most recent round on record is a Series A, in Nov 2022.
What does Mainline Biosciences do?
Mainline Biosciences is a biotechnology company.
Where is Mainline Biosciences headquartered?
Mainline Biosciences is headquartered in Zhongshan, China.
Which VCs invest in companies like Mainline Biosciences?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Mainline Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Mainline Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.